Rchr
J-GLOBAL ID:200901050054075338   Update date: Jul. 16, 2024

Harabayashi Toru

ハラバヤシ トオル | Harabayashi Toru
Affiliation and department:
Job title: Medical director,
Homepage URL  (1): http://www.med.hokudai.ac.jp/~uro-w/
Research field  (1): Urology
Research keywords  (2): 泌尿器腫瘍 ,  Urological Cancer
Research theme for competitive and other funds  (7):
  • 2005 - 2006 In vivo imaging with replication competent retrovirus vector in urologic cancer
  • 2001 - 2003 Elucidation of protective effects of phytochemicals on hormone-related cancer
  • 1999 - 2000 Basic study for the prevention of recurrence by inhibition of cell adhesion and migration in superficial bladder cancer.
  • 泌尿器腫瘍治療後のQOLに関する研究
  • 膀胱癌の進展形式に関する研究
Show all
Papers (145):
  • Taku Murakami, Keita Minami, Toru Harabayashi, Satoru Maruyama, Norikata Takada, Akira Kashiwagi, Haruka Miyata, Yasuyuki Sato, Ryuji Matsumoto, Hiroshi Kikuchi, et al. Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients. Scientific reports. 2024. 14. 1. 6801-6801
  • 樋口 まどか, 佐藤 三穂, 大澤 崇宏, 山田 修平, 宮田 遥, 松本 隆児, 田中 博, 佐々木 芳浩, 森田 研, 原林 透, et al. 膀胱癌術後患者における日本語版Body Image Scaleの信頼性と妥当性の検証. 泌尿器外科. 2023. 36. 臨増. 886-886
  • 樋口 まどか, 佐藤 三穂, 大澤 崇宏, 山田 修平, 宮田 遥, 菊地 央, 松本 隆児, 三浪 圭太, 田中 博, 佐々木 芳浩, et al. 日本語版Body Image Scaleの膀胱癌術後患者における信頼性・妥当性の検証. 泌尿器外科. 2023. 36. 5. 417-417
  • Miho Sato, Takahiro Osawa, Takashige Abe, Michitaka Honda, Madoka Higuchi, Shuhei Yamada, Jun Furumido, Hiroshi Kikuchi, Ryuji Matsumoto, Yasuyuki Sato, et al. Validation of the Japanese version of the Body Image Scale for bladder cancer patients. Scientific reports. 2022. 12. 1. 21544-21544
  • Yurie Hirata, Madoka Higuchi, Takahiro Osawa, Shiro Hinotsu, Toru Harabayashi, Tango Mochizuki, Nobuyasu Enami, Osamu Nounaka, Yuichiro Shinno, Hiroshi Kikuchi, et al. Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods. International journal of urology : official journal of the Japanese Urological Association. 2022. 29. 10. 1140-1146
more...
MISC (132):
  • 秦 浩信, 今待 賢治, 國井 信彦, 江戸 美奈子, 原林 透, 吉川 和人, 北川 善政. デンタルインプラント周囲炎による骨吸収抑制薬関連顎骨壊死 顎骨の病的骨折に至った前立腺癌骨転移の1例. 国立病院総合医学会講演抄録集. 2020. 74回. P-649
  • Hiroyuki Tanaka, Hiroaki Hiraga, Yoh Takekuma, Toru Harabayashi, Satoshi Nagamori, Masayuki Endo, Mitsuru Sugawara. Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer. Biological & pharmaceutical bulletin. 2020. 43. 5. 762-766
  • Yurie Hirata, Takahiro Osawa, Madoka Higuchi, Shiro Hinotsu, Toru Harabayashi, Tango Mochizuki, Nobuyasu Enami, Osamu Nounaka, Yuichiro Shinno, Hiroshi Kikuchi, et al. LATE RECURRENCE OF NON-MUSCLE-INVASIVE BLADDER CANCER AFTER A 5-YEAR CANCER-FREE PERIOD. JOURNAL OF UROLOGY. 2020. 203. E1079-E1080
  • Ryuji Matsumoto, Takashige Abe, Noritaka Takada, Keita Minami, Toru Harabayashi, Satoru Maruyama, Hiroshi Kikuchi, Takahiro Osawa, Nobuo Shinohara. THE EFFECTIVENESS OF TEMPLATE-BASED REGIONAL LYMPH NODE DISSECTION IN REDUCING LOCOREGIONAL RECURRENCE IN PATIENTS WITH CLINICALLY NODE-NEGATIVE UPPER URINARY TRACT UROTHELIAL CARCINOMA. JOURNAL OF UROLOGY. 2020. 203. E375-E376
  • Keita Minami, Takahiro Osawa, Taku Murakami, Hiroshi Harada, Toru Harabayashi, Norikata Takada, Akira Kashiwagi, Kazushi Hirakawa, Yasuyuki Sato, Ryuji Matsumoto, et al. URINARY EXTRACELLULAR VESICLE RNA BIOMARKERS FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER. JOURNAL OF UROLOGY. 2020. 203. E1008-E1009
more...
Education (2):
  • - 1987 Hokkaido University School of Medicine
  • - 1987 Hokkaido University Faculty of Medicine
Professional career (1):
  • Medicine (Hokkaido University)
Work history (2):
  • 1995 - 1996 がん研究振興財団リサーチレジデント
  • 1995 - 1996 Foundation for Promotion of Cancer research , resident
Association Membership(s) (6):
日本ESWL Endourology学会 ,  日本内視鏡外科学会 ,  American Uropogical Associattion Cornespoudirg ,  日本癌学会 ,  日本癌治療学会 ,  日本泌尿器科学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page